Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.

Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating ...

Colossal Biosciences is now valued at over $10 billion and is working on ambitious projects to resurrect multiple long ...

It's clear though that these companies need time. Even with the only approved CAS9 based treatment out there, CRISPR is still years away from achieving its potential. In a recent update to ...

CRISPR-Cas9 is one of the biggest discoveries of the 21st century. Since it was developed in 2012, this gene-editing tool has revolutionized biology research, making it easier to study disease and ...

The paper investigates a potential cause of a type of severe epilepsy that develops in early life because of a defect in a gene called KCNQ2. The significance is fundamental because it substantially ...